[C2F6 in the treatment of retinal detachment associated to PVR: therapeutic trial].
We conducted a clinical trial on C2F6 as a retinal tamponade in the management of retinal detachment with proliferative vitreoretinopathy. Twenty seven eyes of 27 consecutive patients were enrolled in the study. Permanent retinal reattachment was achieved in 21 eyes (78%). The anatomic success rate was 85% in eyes with grade B PVR (17/20 eyes), and 57% in eyes with grade C and D PVR (4/7 eyes). The success rate was as high as that achieved in a previous series of eyes managed with the use of C3F8 combined with the same surgical technique. C2F6 shares the advantages of C3F8 in the management of retinal detachments complicated by proliferative vitreoretinopathy. However its absorption is more rapid as compared to C3F8. This is an advantage with regard to the postoperative disadvantages of gas tamponade. Further clinical use on a larger series of patients is required to confirmed the preliminary results.